Nimesulida Pharmakern (Nimesulide)

• Nimesulide is indicated for conditions involving pain and inflammation, primarily affecting the musculoskeletal and gynecologic systems.
• Mild to moderate pain: provides analgesic relief for headaches, dental pain, postoperative discomfort and other acute pain states.
• Osteoarthritis: reduces joint inflammation and improves mobility in patients with degenerative joint disease.
• Dysmenorrhea: alleviates menstrual cramps by decreasing uterine prostaglandin production.
• Fever: offers antipyretic effect to reduce elevated body temperature in acute febrile episodes.

• Nimesulide selectively inhibits the cyclooxygenase‑2 (COX‑2) enzyme, which catalyzes the conversion of arachidonic acid to prostaglandins. By reducing COX‑2 activity, the drug lowers the synthesis of prostaglandins that mediate inflammation, pain and fever, while sparing COX‑1–mediated protective gastric functions. This selective action underlies its analgesic, anti‑inflammatory and antipyretic properties. The inhibition is reversible and dose‑dependent, allowing modulation of the inflammatory response without complete blockade of prostaglandin pathways.

Nimesulide may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects

• Gastrointestinal discomfort: mild stomach pain or indigestion.
• Nausea: feeling of sickness often occurring shortly after intake.
• Headache: transient head pain of mild to moderate intensity.
• Dizziness: brief episodes of light‑headedness or unsteadiness.

Serious or Rare Side Effects

• Hepatotoxicity: elevated liver enzymes or clinically significant liver injury.
• Severe skin reactions: such as Stevens‑Johnson syndrome or toxic epidermal necrolysis.
• Renal impairment: reduced kidney function or acute kidney injury.

Before prescribing Nimesulide, clinicians should evaluate patient history and monitor specific parameters to minimize risk.

• Assess liver function: obtain baseline liver enzyme tests and repeat periodically during prolonged therapy.
• Evaluate renal status: check kidney function especially in elderly, dehydrated or volume‑depleted patients.
• Avoid in known NSAID hypersensitivity: patients with previous allergic reactions to NSAIDs should not receive the drug.
• Use the lowest effective dose: limit duration to the shortest period necessary to reduce gastrointestinal and cardiovascular risks.
• Caution with concomitant hepatotoxic agents: avoid combining with drugs such as isoniazid, methotrexate or extensive alcohol use.
• Store at room temperature: keep in the original packaging, protect from moisture and direct light.

Nimesulide can interact with several medicines, altering efficacy or increasing toxicity.

Major Interactions (Avoid)

• Concurrent use with other NSAIDs or COX‑2 inhibitors: markedly raises risk of gastrointestinal bleeding and ulceration.
• Combination with anticoagulants (e.g., warfarin, heparin) or antiplatelet agents: enhances anticoagulant effect and may cause serious bleeding.
• Co‑administration with hepatotoxic drugs (e.g., isoniazid, methotrexate, azathioprine): increases potential for liver injury.
• Use with selective serotonin reuptake inhibitors (SSRIs) or serotonin‑norepinephrine reuptake inhibitors (SNRIs): may potentiate bleeding tendencies.

Moderate Interactions (Monitor Closely)

• Concomitant diuretics or ACE inhibitors: may impair renal function, requiring monitoring of creatinine and electrolytes.
• Combination with antihypertensive agents: Nimesulide can reduce the antihypertensive response, necessitating blood pressure checks.
• Interaction with oral contraceptives: may induce hepatic enzymes and slightly reduce contraceptive effectiveness.